Abstract
Boschniakine, a bioalkaloid isolated from the Tecoma stans plant, has been reported to be traditionally utilized for the management of diabetes in model systems through multiple biochemical mechanisms. Studies on Boschniakine are sparse, also, taking into consideration that poor absorption, a rapid metabolic rate, and rapid systemic elimination could limit bioalkaloids’ pharmacological efficacy. To recognize such limitations, we propose the use of highly bioavailable Boschniakine-Solid Lipid Nanoparticles (Bos-SLNPs). This study examined the potential molecular mechanisms underlying the anti-diabetic effects of Bos-SLNP. Bos-SLNP (25 and 50 mg/kg) was evaluated for 30 days for its antidiabetic activity in streptozotocin-induced Type 1 and Type 2 diabetic rats. In addition, the RT-PCR technique was used to determine messenger-RNA expression of Interleukin-1, Interleukin-6, and Tumor Necrosis Factor-alpha in renal tissue. haematoxylin and eosin staining and Western blotting were used to find differences in the nuclear factor erythroid 2-related factor 2/heme oxygenase/Nuclear Factor-κB signaling pathway and how its proteins were expressed. Bos-SLNPs treatment resulted in an increase in the expression of nuclear factors erythroid 2-related factor 2 and heme oxygenase-1 and a decrease in the expression of Nuclear factor-B. This was because Bos-SLNPs have a protective mechanism, which comes from their anti-inflammatory and anti-oxidant properties. Bos-SLNPs exhibited a protective effect against diabetic nephropathy in rats induced with streptozocin, possibly via the nuclear factor erythroid 2-related factor pathway 2 / heme oxygenase 1/ nuclear factor B.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
